Drugs /

2-hydroxyoleic acid

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration, 2-hydroxyoleic acid (2OHOA) activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.

Clinical Trials

View Clinical Trials for 2-hydroxyoleic acid

2-hydroxyoleic acid has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating 2-hydroxyoleic acid, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open).

Malignant solid tumor is the most common disease being investigated in 2-hydroxyoleic acid clinical trials [2].

Drug Details

Synonyms [2]:
2-hydroxy-9-cis-octadecenoic acid, minerval, 2-ohoa compound, 2-ohoa, 2ohoa
NCIT ID [1]:
C105401

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.